The high expression of MYL9 in breast cancer, esophageal squamous cell carcinoma, liver cancer, and epithelial ovarian cancer is associated with poor prognosis, while the low expression of MYL9 in non-small cell lung cancer, bladder cancer, and prostate cancer is associated with poor prognosis [11, 12]. This evidence concerns the gene MYL9 and Familial prostate cancer.